IDiyas

For the Inventor, By the Inventor

Hoboken, NJ, United States of America

Ahmet Kekec

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 10.3

ph-index = 4

Forward Citations = 40(Granted Patents)


Location History:

  • Jersey City, NJ (US) (2014 - 2018)
  • Hoboken, NJ (US) (2013 - 2023)

Company Filing History:

goldMedal14 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 1 
 
Merck Shapr & Dohme Corp.
 patent
bronzeMedal1 out of 63 
 
Metabasis Therapeutics, Inc.
 patents
4. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11820805 - Conjugate based systems for controlled insulin delivery (2023-11-21),
2. 11530250 - Tyrosine-specific functionalized insulin and insulin analogs (2022-12-20),
3. 11041009 - Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes (2021-06-22),
4. 10800827 - Insulin receptor partial agonists (2020-10-13),
5. 10689430 - Insulin receptor partial agonists (2020-06-23),
6. 10183981 - Insulin receptor partial agonists (2019-01-22),
7. 10017556 - Insulin receptor partial agonists (2018-07-10),
8. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),
9. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),
10. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),
11. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),
12. 9382243 - Azabenzimidazole tetrahydropyran derivatives (2016-07-05),
13. 9290517 - Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives (2016-03-22),
14. 8895596 - Cyclic benzimidazole derivatives useful as anti-diabetic agents (2014-11-25),
15. 8410284 - Cyclic benzimidazole derivatives useful as anti-diabetic agents (2013-04-02),

Title: The Innovative Journey of Inventor Ahmet Kekec

Introduction

Ahmet Kekec is a distinguished inventor based in Hoboken, NJ, USA, known for his remarkable contributions to the field of insulin delivery systems. With a portfolio of 16 patents, Kekec has significantly impacted medicine, especially in diabetes management, through his innovative research and inventions.

Latest Patents

Kekec's latest patents include groundbreaking advancements such as "Conjugate Based Systems for Controlled Insulin Delivery" and "Tyrosine-Specific Functionalized Insulin and Insulin Analogs". The first patent outlines a conjugate framework that links insulin molecules with separate saccharide ligands, designed for enhanced insulin delivery. This system has the potential for improved pharmacokinetic and pharmacodynamic properties, optimizing treatment for individuals requiring insulin therapy. The second patent focuses on functionalized insulin analogs using specific chemical processes, paving the way for new treatment methodologies for diabetes.

Career Highlights

Throughout his career, Ahmet Kekec has made significant strides in pharmaceutical research, particularly while working at Merck Sharp & Dohme Corporation and Merck Sharp & Dohme Corp. His dedication to advancing diabetes treatment through innovative insulins and delivery systems showcases his expertise and commitment to improving patient outcomes.

Collaborations

Kekec has collaborated with notable researchers such as Danqing D Feng and Zhicai Wu. These collaborations have fostered an environment of creativity and scientific inquiry, resulting in advancements that have the potential to transform the landscape of diabetes therapy.

Conclusion

Ahmet Kekec's innovative spirit and dedication to improving insulin delivery systems through his 16 patents highlight his status as a prominent inventor in the medical field. His work not only encapsulates creativity but also addresses the crucial need for effective diabetes management, making a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…